The Experts below are selected from a list of 262440 Experts worldwide ranked by ideXlab platform
R Eastell - One of the best experts on this subject based on the ideXlab platform.
-
treatment of postmenopausal Osteoporosis
The New England Journal of Medicine, 1998Co-Authors: R EastellAbstract:Osteoporosis affects an estimated 75 million people in Europe, the United States, and Japan.1 It is a preventable and treatable condition, yet many people with Osteoporosis remain unrecognized and untreated. The purpose of this review is to consider the evidence that treatments for postmenopausal Osteoporosis are effective and safe. Definition of Osteoporosis Definitions of Osteoporosis have usually been conceptual and therefore difficult to apply to individual patients. For example, a Consensus Development Conference defined Osteoporosis as “a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration with a consequent increase in bone fragility and susceptibility to fracture.”1 A . . .
Jeanmarc Feron - One of the best experts on this subject based on the ideXlab platform.
-
2012 update of french guidelines for the pharmacological treatment of postmenopausal Osteoporosis
Joint Bone Spine, 2012Co-Authors: Karine Briot, Bernard Cortet, Thierry Thomas, Maurice Audran, H Blain, Veronique Breuil, Laure Chapuis, Roland Chapurlat, Patrice Fardellone, Jeanmarc FeronAbstract:Abstract Objectives To update the evidence-based position statement published by the French National Authority for Health (HAS) in 2006 regarding the pharmacological treatment of postmenopausal Osteoporosis, under the auspices of the French Society for Rheumatology and Groupe de Recherche et d’Information sur les Osteoporoses (GRIO), and with the participation of several learned societies (College National des Gynecologues et Obstetriciens Francais, Groupe d’Etude de la Menopause et du Vieillissement hormonal, Societe Francaise de Chirurgie Orthopedique, Societe Francaise d’Endocrinologie, and Societe Francaise de Geriatrie et de Gerontologie). Methods A multidisciplinary panel representing the spectrum of clinical specialties involved in managing patients with postmenopausal Osteoporosis developed updated recommendations based on a systematic literature review conducted according to the method advocated by the HAS. Results The updated recommendations underline the need for Osteoporosis pharmacotherapy in women with a history of severe osteoporotic fracture. In these patients, any Osteoporosis medication can be used; however, zoledronic acid is the preferred first-line medication after a hip fracture. In patients with non-severe fractures or no fractures, the appropriateness of Osteoporosis pharmacotherapy depends on the bone mineral density and FRAX ® values; any Osteoporosis medication can be used, but raloxifene and ibandronate should be reserved for patients at low risk for peripheral fractures. Initially, Osteoporosis pharmacotherapy should be prescribed for 5 years. The results of the evaluation done at the end of the 5-year period determine whether further treatment is in order. Conclusions These updated recommendations are intended to provide clinicians with clarifications about the pharmacological treatment of Osteoporosis.
C Cooper - One of the best experts on this subject based on the ideXlab platform.
-
Osteoporosis burden health care provision and opportunities in the eu a report prepared in collaboration with the international Osteoporosis foundation iof and the european federation of pharmaceutical industry associations efpia
Archives of Osteoporosis, 2011Co-Authors: O Strom, J E Compston, C Cooper, J A Kanis, E V Mccloskey, F Borgstrom, Bengt JonssonAbstract:Osteoporosis, literally "porous bone", is a disease characterized by weak bone. It is a major public health problem, affecting hundreds of millions of people worldwide, predominantly postmenopausal women. The main clinical consequence of the disease is bone fractures. It is estimated that one in three women and one in five men over the age of fifty worldwide will sustain an osteoporotic fracture. Hip and spine fractures are the two most serious fracture types, associated with substantial pain and suffering, disability, and even death. As a result, Osteoporosis imposes a significant burden on both the individual and society. During the past two decades, a range of medications has become available for the treatment and prevention of Osteoporosis. The primary aim of pharmacological therapy is to reduce the risk of osteoporotic fractures. The objective of this report is to review and describe the current burden of Osteoporosis and highlight recent advances and ongoing challenges for treatment and prevention of the disease. The report encompasses both epidemiological and health economic aspects of Osteoporosis and osteoporotic fractures with a primary geographic focus on France, Germany, Italy, Spain, Sweden, and the UK. Projections of the future prevalence of Osteoporosis and fracture incidence, the total societal burden of the disease, and the consequences of different intervention strategies receive special attention. The report may serve as a basis for the formulation of healthcare policy concerning Osteoporosis in general and the treatment and prevention of Osteoporosis in particular. It may also provide guidance regarding the overall healthcare priority of the disease. © International Osteoporosis Foundation and National Osteoporosis Foundation 2011.
-
guidelines for the diagnosis and management of Osteoporosis in postmenopausal women and men from the age of 50 years in the uk
Maturitas, 2009Co-Authors: J E Compston, A Cooper, C Cooper, R Francis, J A Kanis, D Marsh, E V Mccloskey, D M Reid, P L Selby, Marc R WilkinsAbstract:In 1999 and 2000 the Royal College of Physicians published guidelines for the prevention and treatment of Osteoporosis [Royal College of Physicians. Osteoporosis: clinical guidelines for the prevention and treatment. London: Royal College of Physicians; 1999; Royal College of Physicians and Bone and Tooth Society of Great Britain. Update on pharmacological interventions and an algorithm for management. London, UK: Royal College of Physicians; 2000.; Royal College of Physicians. Glucocorticoid-induced Osteoporosis. Guidelines on prevention and treatment; Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. London, UK: Royal College of Physicians; 2002]. Since then, there have been significant advances in the field of Osteoporosis including the development of new techniques for measuring bone mineral density, improved methods of assessing fracture risk and new treatments that have been shown to significantly reduce the risk of fractures. Against this background, the National Osteoporosis Guideline Group (NOGG), in collaboration with many Societies in the UK, have updated the original guidelines [Royal College of Physicians, National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society, British Orthopaedic Association, British Society of Rheumatology, National Osteoporosis Society, Osteoporosis 2000, Osteoporosis Dorset, Primary Care Rheumatology Society, Society for Endocrinology. Osteoporosis. Clinical guideline for prevention and treatment, Executive Summary. University of Sheffield Press; 2008], a practical summary of which is detailed below. The management algorithms are underpinned by a health economic analysis applied to the epidemiology of fracture in the UK.
-
guidelines for diagnosis and management of Osteoporosis
Osteoporosis International, 1997Co-Authors: J A Kanis, C Cooper, P D Delmas, P Burckhardt, David J TorgersonAbstract:Significant developments have occurred in the field of Osteoporosis over the past several years. There is now considerable information concerning its impact on general health and an international consensus concerning the definition of Osteoporosis. Conceptually, this recognizes the multifactorial nature of the events which give rise to the fractures, but operational definitions have now been agreed and have gained a wide measure of acceptance. Accurate and precise diagnostic tools are also available. Finally, there is substantial evidence that the natural history of Osteoporosis can be modulated by agents which in turn decrease the risk of fracture. Despite an increasing professional and public awareness of Osteoporosis, the management of Osteoporosis has been confined mainly to specialists. With the large number of affected individuals and the wider availability of diagnostic aids and safe treatments, there is a need for Osteoporosis to be managed predominantly by the primary care physician. Against this background the European Foundation for Osteoporosis and Bone Disease through their Scientific Advisory Board has recognized a need to develop practice guidelines for primary care physicians which are summarized in this paper.
Andrew J Palmer - One of the best experts on this subject based on the ideXlab platform.
-
microsimulation model for the health economic evaluation of Osteoporosis interventions study protocol
BMJ Open, 2019Co-Authors: Lei Si, Tania Winzenberg, Kerrie M Sanders, Tuan V Nguyen, John A Eisman, Andrew J PalmerAbstract:Introduction Osteoporosis is a systemic skeletal disease that is characterised by reduced bone strength and increased fracture risk. Osteoporosis-related fractures impose enormous disease and economic burden to the society. Although many treatments and health interventions are proven effective to prevent fractures, health economic evaluation adds evidence to their economic merits. Computer simulation modelling is a useful approach to extrapolate clinical and economic outcomes from clinical trials and it is increasingly used in health economic evaluation. Many Osteoporosis health economic models have been developed in the past decades; however, they are limited to academic use and there are no publicly accessible health economic models of Osteoporosis. Methods and analysis We will develop the Australian Osteoporosis health economic model based on our previously published microsimulation model of Osteoporosis in the Chinese population. The development of the model will follow the recommendations for the conduct of economic evaluations in Osteoporosis by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and the US branch of the International Osteoporosis Foundation. The model will be a state-transition semi-Markov model with memory. Clinical parameters in the model will be mainly obtained from the Dubbo Osteoporosis Epidemiology Study and the health economic parameters will be collected from the Australian arm of the International Costs and Utilities Related to Osteoporotic Fractures Study. Model transparency and validates will be tested using the recommendations from Good Research Practices in Modelling Task Forces. The model will be used in economic evaluations of Osteoporosis interventions including pharmaceutical treatments and primary care interventions. A user-friendly graphical user interface will be developed, which will connect the user to the calculation engine and the results will be generated. The user interface will facilitate the use of our model by people in different sectors. Ethics and dissemination No ethical approval is needed for this study. Results of the model validation and future economic evaluation studies will be submitted to journals. The user interface of the health economic model will be publicly available online accompanied with a user manual.
Inesia Putri Wulandari - One of the best experts on this subject based on the ideXlab platform.
-
hubungan antara tingkat pengetahuan tentang Osteoporosis dengan asupan kalsium pada wanita premenopause di puskesmas cinangka banten tahun 2017
Jurnal Ilmu Kedokteran dan Kesehatan, 2018Co-Authors: Tessa Sjahriani, Inesia Putri WulandariAbstract:Latar Belakang: Penelitian terbaru dari International Osteoporosis Foundation (IOF) mengungkapkan bahwa 1 dari 4 perempuan di Indonesia dengan rentang usia 50- 80 tahun memiliki risiko terkena Osteoporosis. Badan Litbang Gizi Depkes RI tahun 2006,menunjukkan angka prevalensi osteopenia (Osteoporosis dini) adalah 41,7% dan prevalensi Osteoporosis sebesar 10,3% yang berarti 2 dari 5 penduduk Indonesia berisiko terkena Osteoporosis. Hasil analisa Depkes yang dilakukan di 14 propinsi menunjukkan masalah Osteoporosis telah mencapai pada tingkat perlu diwaspadai yaitu sekitar 19,7% dari jumlah lansia yang ada (Depkes RI, 2006).Hal itu ditandai juga dengan rendahnya konsumsi kalsium rata-rata orang Indonesia, yakni hanya 254 mg per hari (Thanaseelan, 2010). Tujuan Penelitian: Untuk mengetahui hubungan tingkat pengetahuan tentang Osteoporosis dengan asupan kalsium pada wanita premenopause di Puskesmas Cinangka, BantenTahun 2017. Metode Penelitian: Jenis penelitian kuantitatif, desain analitik dengan pendekatan cross sectional yaitu menggunakan data primer dengan populasi penelitian adalah wanita dalam periode premenopause yang berusia antara 40-50 tahun sebanyak 3960 orang, dengan sampel sebanyak 128 orang.Teknik sampling penelitian ini menggunakan Simple Random Sampling. Analisis data menggunakan UjiChi Square. Hasil: Terdapat hubungan tingkat pengetahuan tentang Osteoporosis dengan asupan kalsium (p 0,000) OR=13,765. Kesimpulan:Terdapat hubungan tingkat pengetahuan tentang Osteoporosis dengan asupan kalsium pada wanita premenopause di Puskesmas Cinangka, BantenTahun 2017.
